AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02012413 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sham PST
Description: Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes
Study NCT04080505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSKI- Potassium Iodide
Description: 1g/mL, 2 drops orally 3 times a day for 7 days before surgery
Study NCT00706433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminolevulinic acid HCL (ALA)
Description: Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
Study NCT00706433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (VEH)
Description: Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
Study NCT02391857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric decompression
Description: Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
Study NCT01614743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Experimental injection given at baseline and Week 16
Study NCT01614743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic saline
Description: Placebo at baseline, incobotulinumtoxinA at 16 weeks
Study NCT02853253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMOFlipid®
Description: SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively.
Study NCT02853253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medialipide®
Description: Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively.
Study NCT02441712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS
Study NCT02441712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PENS
Study NCT01510522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage
Description: Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
Study NCT01510522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage
Description: Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: > 1.700mg/day for 6 month
Study NCT01259284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
Study NCT01259284 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplement
Description: 3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
Study NCT01259284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.
Study NCT01259284 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.
Study NCT03809741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled L&D Infection Prevention Interventions
Description: The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy
Study NCT03549312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48.
Study NCT03549312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96.
Study NCT03549312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96.
Study NCT03039257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin A
Description: Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
Study NCT03333837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dance Group
Description: Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.
Study NCT03333837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Group Dance
Description: The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.
Study NCT03333837 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Group
Description: The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.
Study NCT03333837 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Contact
Description: The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.
Study NCT01640275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: patients randomized to the propofol arm of the study will receive general anesthesia with propofol
Study NCT01640275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
Study NCT04671134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biomimetic remineralizing agent
Description: Self-assempling peptide
Study NCT04671134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biomimetic remineralizing agent
Description: Self-assempling peptide
Study NCT04671134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resin Modified Glass Ionomer Varnish
Description: Resin Modified Glass Ionomer Varnish
Study NCT04671134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin Modified Glass Ionomer Varnish
Description: Resin Modified Glass Ionomer Varnish
Study NCT05350579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogurt Intervention
Description: Participants will be asked to consume one serving of yogurt per day.~Nutrient composition of yogurt provided to participants in the yogurt group:~Nutrients per serving Serving Size: 141 g Energy (kcal) 170 Total Fat (g) 8 Total Carbohydrate (g) 16 Sugars (g) 15 Protein (g) 5 Sodium (mg) 85 Calcium (%) 15 Vitamin A (%) 4 Ingredients: Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (S. thermophilus, L. bulgaricus), Vanilla Extract.
Study NCT04270630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Aid
Description: The decision aid was developed by this study group based on the International Patient Decision Aid Standards Collaboration's minimum standards for quality, and the Ottawa Framework (a process by which patients' and clinicians' decision determinants are assessed, a decision aid is developed that is tailored to these needs, and the quality of the decision-making process with the aid is evaluated). The aid then underwent an iterative feedback process with a patient advisory panel. Adjustments to format, length, and readability were made. A final feedback session occurred with three patients over the age of 70, after which point the paper decision aid was digitalized. The intervention will be delivered in-person by one of the co-investigators of the study. The intervention will occur once, prior to the patient making a final decision regarding undergoing left heart catheterization as treatment for NSTEMI. The approximate duration of the intervention is 30 minutes.
Study NCT00001563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
Study NCT00001563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: EPOCH-R every 3 weeks for up to 6 cycle
Study NCT00001563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: EPOCH-R every 3 weeks for up to 6 cycle
Study NCT02425930 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy plus D2 lymphadenectomy
Description: A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
Study NCT02425930 — intervention group
Intervention type: DRUG
Intervention: S-1+Oxaliplatin
Description: A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:~* S-1: 40\~60mg bid，po, Day1\~14 （S-1：BSA \<1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）~* Oxaliplatin: 130mg/m2，iv drip for 2h，Day1
Study NCT01906554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Dose
Description: Different quantities of eggs
Study NCT02369445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moisture Pager Intervention for Toilet Training
Study NCT02369445 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Study NCT00002565 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00002565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT04793802 — intervention group
Intervention type: OTHER
Intervention: PHYSIO
Description: session of physiotherapy
Study NCT00938704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboxymethylcellulose 0.5% +glycerin 0.9%
Description: To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
Study NCT00938704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium hyaluronate 0.18%
Description: To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
Study NCT04081103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® (lufepirsen) High Dose Concentration
Description: Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Study NCT04081103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexagon® (lufepirsen) Low Dose Concentration
Description: Nexagon® (lufepirsen) is administered topically in the affected eye three (3) times over 28 days.
Study NCT04081103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle is administered topically in the affected eye three (3) times over 28 days.
Study NCT04081103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label Nexagon® (lufepirsen)
Description: Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
Study NCT04081103 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label Nexagon® (lufepirsen)
Description: Open-label Nexagon® (lufepirsen) for participants who do not heal (re-epithelialize) at the end of the 28-day treatment phase.
Study NCT02582775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: 0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
Study NCT02582775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
Study NCT04217590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.
Study NCT04217590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Study NCT00860613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical nutrition therapy program
Description: the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
Study NCT02582775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 IV over 60 minutes days -6 through day -2
Study NCT02582775 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: See arm description for dosing.
Study NCT02582775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow infusion
Description: Bone marrow infusion on Day 0
Study NCT04294732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL.
Study NCT04294732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine is a local anesthetic drug which is already using in surgical procedures.~saline is isotonic solution of which has include %0,9 NACL.
Study NCT04294732 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Only spinal anesthesia without peripheral nerve block
Description: Only spinal anesthesia without peripheral nerve block
Study NCT02594826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally appropriate intervention
Description: Church-based educational intervention combined with navigation assistance
Study NCT02594826 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General health education control
Description: General health and cancer education
Study NCT01321346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
Study NCT01321346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.~All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation.
Study NCT02582775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors). When used in non-MSD recipients, tapered over 6-8 weeks starting at day +100.